Bausch + Lomb Corporation (BLCO) — Analysis Summary
Bausch + Lomb Corporation (BLCO) has a market cap of $5.74B with year-over-year revenue growth of +6.5%. Net margin stands at -7.1%. The stock trades at a P/E ratio of -33.6.
Key Takeaways
- Revenue changed +6.5% year-over-year
- Net margin of -7.1%
- P/E ratio of -33.6
Compared to other companies in the OPHTHALMIC GOODS sector, BLCO posted revenue growth of +6.5% and trades at a P/E of -33.6.
Bausch + Lomb Corporation (BLCO)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 6.9x — highly leveraged, potential refinancing risk
Interest coverage at 0.8x — earnings do not cover interest payments
Operating margin (6.1%) exceeds gross margin (0.0%) — check for other operating income or data classification issues
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Sector
OPHTHALMIC GOODS
Employees
13,000
Headquarters
VAUGHAN, A6
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.